Intellia Therapeutics - NTLA Stock Price Target and Predictions

Target and Analyst Ratings
Price Target History
Upgrades and Downgrades
News Sentiment
About
FAQ

Consensus Rating: Moderate Buy
Consensus Price Target: $67.00
Forecasted Upside: 210.62%
Number of Analysts: 13
Breakdown:
0 Sell Ratings
4 Hold Ratings
9 Buy Ratings
0 Strong Buy Ratings

^$21.57 As of 04/19/2024 01:00 AM ET

▲ +0.25 (1.17%)

1 month | 3 months | 12 months

Get New Intellia Therapeutics Analyst Ratings Delivered To Your Inbox

Sign-up to receive the latest news and ratings for NTLA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for NTLA

^$67.00

▲ +210.62% Upside Potential

This price target is based on 13 analysts offering 12 month price targets for Intellia Therapeutics in the last 3 months. The average price target is $67.00, with a high forecast of $107.00 and a low forecast of $29.00. The average price target represents a 210.62% upside from the last price of $21.57.

Current Consensus is Moderate Buy

The current consensus among 13 contributing investment analysts is to moderate buy stock in Intellia Therapeutics. This Moderate Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
9 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

10/27/2022

0 strong buy ratings
9 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

1/25/2023

0 strong buy ratings
9 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

4/25/2023

0 strong buy ratings
9 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

7/24/2023

0 strong buy ratings
9 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

10/22/2023

0 strong buy ratings
9 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

1/20/2024

0 strong buy ratings
9 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

3/20/2024

0 strong buy ratings
9 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

4/19/2024

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price
2/23/2024	Canaccord Genuity Group	Boost Target	Buy ➝ Buy	$72.00 ➝ $73.00	Low
2/23/2024	The Goldman Sachs Group	Downgrade	Buy ➝ Neutral	$136.00 ➝ $32.00	Low
2/15/2024	Wedbush	Reiterated Rating	Neutral	$29.00	Low
2/15/2024	Wolfe Research	Initiated Coverage	Peer Perform		Low
11/13/2023	Oppenheimer	Lower Target	Outperform ➝ Outperform	$80.00 ➝ $70.00	Low
11/13/2023	Morgan Stanley	Lower Target	Overweight ➝ Overweight	$90.00 ➝ $85.00	Low
11/10/2023	Raymond James	Lower Target	Outperform ➝ Outperform	$78.00 ➝ $57.00	Low
11/10/2023	The Goldman Sachs Group	Lower Target	Buy ➝ Buy	$157.00 ➝ $136.00	Low
11/10/2023	Royal Bank of Canada	Lower Target	Outperform ➝ Outperform	$80.00 ➝ $70.00	Low
11/10/2023	BMO Capital Markets	Lower Target	Outperform ➝ Outperform	$64.00 ➝ $62.00	Low
11/2/2023	Wedbush	Reiterated Rating	Neutral	$45.00	Low
10/18/2023	Wedbush	Reiterated Rating	Neutral	$48.00 ➝ $45.00	Low
9/13/2023	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$65.00	Low
8/29/2023	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$65.00	Low
8/9/2023	Cantor Fitzgerald	Reiterated Rating	Overweight ➝ Overweight	$65.00	Low
8/7/2023	Chardan Capital	Reiterated Rating	Buy ➝ Buy	$107.00	Low
8/7/2023	Canaccord Genuity Group	Lower Target	Buy ➝ Buy	$66.00 ➝ $65.00	Low
8/4/2023	Barclays	Lower Target	Overweight ➝ Overweight	$148.00 ➝ $90.00	Low
8/4/2023	Citigroup	Lower Target	Neutral ➝ Neutral	$44.00 ➝ $40.00	Low
6/13/2023	Bank of America	Boost Target		$89.00 ➝ $91.00	Low
6/13/2023	Chardan Capital	Lower Target		$111.00 ➝ $107.00	Low
5/5/2023	BMO Capital Markets	Boost Target		$57.00 ➝ $64.00	Low
4/13/2023	Canaccord Genuity Group	Initiated Coverage	Buy	$66.00	Low
3/31/2023	JPMorgan Chase & Co.	Lower Target	Overweight	$82.00 ➝ $79.00	Low
3/22/2023	William Blair	Reiterated Rating	Outperform		Low
3/21/2023	Sanford C. Bernstein	Initiated Coverage	Outperform	$54.00	Low
3/13/2023	BMO Capital Markets	Upgrade	Market Perform ➝ Outperform	$54.00 ➝ $57.00	Low
2/24/2023	Chardan Capital	Lower Target	Buy	$129.00 ➝ $111.00	Low
2/24/2023	Raymond James	Lower Target	Outperform	$124.00 ➝ $94.00	Low
2/24/2023	EF Hutton Acquisition Co. I	Lower Target	Buy	$123.00 ➝ $116.00	Low
2/24/2023	Oppenheimer	Lower Target	Outperform	$115.00 ➝ $93.00	N/A
2/24/2023	Credit Suisse Group	Lower Target	Outperform	$88.00 ➝ $76.00	Low
2/24/2023	Robert W. Baird	Lower Target	Neutral	$58.00 ➝ $42.00	Low
1/31/2023	Cantor Fitzgerald	Initiated Coverage	Overweight	$67.00	Low
1/24/2023	Citigroup	Upgrade	Sell ➝ Neutral	$48.00 ➝ $39.00	Low
1/23/2023	SVB Leerink	Lower Target	Outperform	$86.00 ➝ $84.00	Low
1/19/2023	JMP Securities	Downgrade	Outperform ➝ Market Perform		Low
1/4/2023	Wells Fargo & Company	Lower Target	Overweight	$135.00 ➝ $120.00	Low
12/6/2022	Credit Suisse Group	Lower Target	Outperform	$109.00 ➝ $88.00	Low
12/2/2022	SVB Leerink	Lower Target	Outperform	$90.00 ➝ $86.00	Low
11/14/2022	Chardan Capital	Boost Target	Buy	$121.00 ➝ $129.00	Low
11/4/2022	Morgan Stanley	Lower Target	Overweight	$84.00 ➝ $83.00	Low
11/4/2022	Raymond James	Lower Target	Outperform	$127.00 ➝ $124.00	Low
11/4/2022	Credit Suisse Group	Boost Target	Outperform	$101.00 ➝ $109.00	N/A
11/3/2022	Chardan Capital	Lower Target	Buy	$146.00 ➝ $121.00	Low
11/1/2022	EF Hutton Acquisition Co. I	Initiated Coverage	Buy	$130.00	Low
10/11/2022	Morgan Stanley	Initiated Coverage	Overweight	$84.00	Low
9/21/2022	JPMorgan Chase & Co.	Initiated Coverage	Overweight	$85.00	Low
9/19/2022	SVB Leerink	Boost Target	Outperform	$152.00 ➝ $158.00	Low
9/19/2022	JMP Securities	Boost Target	Market Outperform	$106.00 ➝ $111.00	Low
9/16/2022	Chardan Capital	Reiterated Rating	Buy	$146.00	Low
9/1/2022	Citigroup	Initiated Coverage	Sell	$50.00	Low
8/9/2022	Credit Suisse Group	Boost Target		$101.00	Low
8/5/2022	SVB Leerink	Lower Target	Outperform	$155.00 ➝ $152.00	Low
8/5/2022	Chardan Capital	Lower Target	Buy	$172.00 ➝ $146.00	Low
6/16/2022	BMO Capital Markets	Initiated Coverage	Market Perform	$54.00	High
6/16/2022	Bank of America	Initiated Coverage	Buy	$70.00	Medium
5/24/2022	The Goldman Sachs Group	Lower Target	Buy	$206.00 ➝ $180.00	Low
5/9/2022	Oppenheimer	Lower Target		$160.00 ➝ $130.00	High
5/9/2022	JMP Securities	Lower Target		$165.00 ➝ $110.00	High
4/28/2022	Credit Suisse Group	Initiated Coverage	Outperform	$100.00	Medium
3/21/2022	JMP Securities	Reiterated Rating	Buy	$165.00	High
3/7/2022	Brookline Capital Acquisition	Upgrade	Hold ➝ Buy	$91.00	Low
3/7/2022	Brookline Capital Management	Upgrade	Hold ➝ Buy	$91.00	High
3/1/2022	Chardan Capital	Lower Target	Buy	$177.00 ➝ $172.00	High
3/1/2022	Robert W. Baird	Lower Target		$146.00 ➝ $83.00	High
2/18/2022	William Blair	Initiated Coverage	Outperform	$144.00	High
2/14/2022	Brookline Capital Acquisition	Initiated Coverage	Hold		Low
2/14/2022	Brookline Capital Management	Reiterated Rating	Buy		Low
2/7/2022	Oppenheimer	Upgrade	Market Perform ➝ Outperform	$145.00 ➝ $150.00	High
1/31/2022	Cowen	Initiated Coverage	Outperform		High
1/7/2022	JMP Securities	Lower Target	Market Outperform	$175.00 ➝ $165.00	Low
1/7/2022	Piper Sandler	Initiated Coverage	Overweight	$171.00	Low
11/5/2021	Oppenheimer	Lower Target	Market Perform	$160.00 ➝ $145.00	Low
11/5/2021	HC Wainwright	Boost Target	Buy	$171.00 ➝ $182.00	Medium
10/21/2021	HC Wainwright	Reiterated Rating	Buy	$172.00	Medium
10/5/2021	Guggenheim	Initiated Coverage	Buy	$170.00	Low
9/23/2021	Stifel Nicolaus	Initiated Coverage	Buy	$173.00	High
9/16/2021	Chardan Capital	Reiterated Rating	Buy	$177.00	Low
9/13/2021	HC Wainwright	Reiterated Rating	Buy	$171.00	Medium
8/6/2021	JMP Securities	Boost Target	Market Outperform	$160.00 ➝ $175.00	Medium
8/6/2021	The Goldman Sachs Group	Boost Target	Buy	$225.00 ➝ $252.00	Medium
8/6/2021	Oppenheimer	Boost Target	Market Perform	$125.00 ➝ $160.00	Medium
8/6/2021	Chardan Capital	Boost Target	Buy	$130.00 ➝ $177.00	Low
8/6/2021	Raymond James	Boost Target	Outperform	$168.00 ➝ $181.00	Low
8/5/2021	Roth Capital	Boost Target	Buy	$110.00 ➝ $180.00	Medium
7/7/2021	Chardan Capital	Reiterated Rating	Buy		Medium
7/1/2021	Robert W. Baird	Reiterated Rating	Hold	$85.00	High
6/29/2021	Oppenheimer	Boost Target	Market Perform	$73.00 ➝ $125.00	High
6/29/2021	Raymond James	Boost Target	Outperform	$106.00 ➝ $168.00	High
6/28/2021	Royal Bank of Canada	Boost Target	Outperform	$110.00 ➝ $150.00	High
6/28/2021	Truist Financial	Boost Target	Buy	$80.00 ➝ $160.00	High
6/28/2021	Wedbush	Boost Target	Neutral	$73.00 ➝ $87.00	High
6/28/2021	Roth Capital	Boost Target	Buy	$80.00 ➝ $110.00	High
6/28/2021	The Goldman Sachs Group	Boost Target	Buy	$115.00 ➝ $163.00	High
6/28/2021	Barclays	Boost Target	Positive ➝ Overweight	$88.00 ➝ $134.00	High
6/28/2021	HC Wainwright	Boost Target	Buy	$111.00 ➝ $171.00	High
6/26/2021	Chardan Capital	Boost Target	Buy	$85.00 ➝ $130.00	High
6/23/2021	Robert W. Baird	Boost Target	Positive ➝ Neutral	$60.00 ➝ $85.00	High
6/23/2021	JMP Securities	Boost Target	Positive ➝ Outperform	$80.00 ➝ $88.00	High
6/22/2021	Jefferies Financial Group	Boost Target	Buy	$83.00 ➝ $109.00	High
6/22/2021	HC Wainwright	Reiterated Rating	Buy	$111.00 ➝ $171.00	Low
6/11/2021	HC Wainwright	Initiated Coverage	Buy	$111.00	Medium
6/9/2021	Raymond James	Reiterated Rating	Buy		Low
5/7/2021	Roth Capital	Upgrade	Neutral ➝ Buy	$75.00 ➝ $80.00	Medium
5/3/2021	Royal Bank of Canada	Initiated Coverage	Outperform	$110.00	Medium
3/21/2021	SVB Leerink	Reiterated Rating	Buy		High
3/4/2021	JMP Securities	Initiated Coverage	Outperform	$80.00	High
2/26/2021	Truist Financial	Boost Target		$40.00 ➝ $80.00	High
2/10/2021	Chardan Capital	Boost Target	Buy	$57.50 ➝ $85.00	Low
1/8/2021	Raymond James	Boost Target	Outperform	$39.00 ➝ $106.00	High
1/8/2021	Barclays	Boost Target	Overweight	$46.00 ➝ $90.00	Low
12/22/2020	Robert W. Baird	Downgrade	Outperform ➝ Neutral	$60.00	High
12/21/2020	SVB Leerink	Boost Target	Outperform	$27.00 ➝ $61.00	High
12/7/2020	Wells Fargo & Company	Boost Target	Overweight	$38.00 ➝ $52.00	Medium
11/5/2020	SVB Leerink	Reiterated Rating	Outperform		Medium
10/27/2020	Truist Financial	Initiated Coverage	Buy	$40.00 ➝ $40.00	High
10/27/2020	Summer Street	Initiated Coverage	Buy		High
10/19/2020	Roth Capital	Boost Target	Reduce ➝ Neutral	$16.00 ➝ $26.00	Low
10/14/2020	Wells Fargo & Company	Initiated Coverage	Overweight		Medium
9/30/2020	Oppenheimer	Reiterated Rating	Hold		High
9/18/2020	The Goldman Sachs Group	Initiated Coverage	Buy	$33.00	High
8/6/2020	Chardan Capital	Reiterated Rating	Buy		High
6/2/2020	Credit Suisse Group	Boost Target	Neutral	$19.00 ➝ $21.00	High
6/1/2020	Wedbush	Boost Target	Neutral	$16.00 ➝ $20.00	High
6/1/2020	Chardan Capital	Reiterated Rating	Buy	$57.50	High
5/8/2020	Oppenheimer	Reiterated Rating	Hold		Low
4/2/2020	BTIG Research	Reiterated Rating	Buy	$22.00	Low
3/31/2020	Chardan Capital	Reiterated Rating	Buy	$57.50	High
2/28/2020	Oppenheimer	Upgrade	Market Perform ➝ Outperform		High
2/14/2020	Wedbush	Downgrade	Outperform ➝ Neutral	$21.00 ➝ $16.00	High
2/10/2020	Chardan Capital	Reiterated Rating	Buy	$57.50	Low
1/9/2020	Chardan Capital	Reiterated Rating	Buy	$57.50	Medium
11/1/2019	Raymond James	Upgrade	Market Perform ➝ Outperform	$24.00	High
9/27/2019	Chardan Capital	Set Target	Buy	$57.50	High
7/8/2019	Robert W. Baird	Initiated Coverage	Outperform ➝ Outperform	$23.00	Medium
6/10/2019	Roth Capital	Initiated Coverage	Neutral	$16.00	High
5/28/2019	Chardan Capital	Reiterated Rating	Buy	$57.50	Low
5/3/2019	Wedbush	Upgrade	Neutral ➝ Outperform	$20.00 ➝ $21.00	High

(Data available from 4/20/2019 forward)

News Sentiment Rating

0.96 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

8 very positive mentions
3 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

9/22/2023

7 very positive mentions
9 positive mentions
1 negative mentions
1 very negative mentions

Mentions as of

10/22/2023

1 very positive mentions
13 positive mentions
2 negative mentions
0 very negative mentions

Mentions as of

11/21/2023

0 very positive mentions
2 positive mentions
0 negative mentions
0 very negative mentions

Mentions as of

12/21/2023

11 very positive mentions
10 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

1/20/2024

9 very positive mentions
12 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

2/19/2024

18 very positive mentions
16 positive mentions
2 negative mentions
1 very negative mentions

Mentions as of

3/20/2024

10 very positive mentions
5 positive mentions
1 negative mentions
0 very negative mentions

Mentions as of

4/19/2024

Current Sentiment

Recent Stories by Sentiment

Very Negative

No very negative mentions tracked during this time.

Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $21.57

$20.78

$21.63

50 Day Range

MA: $27.21

$21.32

$32.80

52 Week Range

Now: $21.57

$20.78

$47.48

Volume

1,457,139 shs

Average Volume

1,517,656 shs

Market Capitalization

$2.08 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.77

Frequently Asked Questions

What sell-side analysts currently cover shares of Intellia Therapeutics?: The following Wall Street sell-side analysts have issued stock ratings on Intellia Therapeutics in the last year: Bank of America Co., Barclays PLC, BMO Capital Markets, Canaccord Genuity Group Inc., Cantor Fitzgerald, Chardan Capital, Citigroup Inc., Morgan Stanley, Oppenheimer Holdings Inc., Raymond James, Royal Bank of Canada, StockNews.com, The Goldman Sachs Group, Inc., Wedbush, and Wolfe Research.
View the latest analyst ratings for NTLA.
What is the current price target for Intellia Therapeutics?: 13 Wall Street analysts have set twelve-month price targets for Intellia Therapeutics in the last year. Their average twelve-month price target is $67.00, suggesting a possible upside of 210.6%. Chardan Capital has the highest price target set, predicting NTLA will reach $107.00 in the next twelve months. Wedbush has the lowest price target set, forecasting a price of $29.00 for Intellia Therapeutics in the next year.
View the latest price targets for NTLA.
What is the current consensus analyst rating for Intellia Therapeutics?: Intellia Therapeutics currently has 4 hold ratings and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for NTLA.
What other companies compete with Intellia Therapeutics?: Other companies that are similar to Intellia Therapeutics include Celldex Therapeutics, Myriad Genetics, Neogen, QuidelOrtho and Meridian Bioscience. Learn More about companies similar to Intellia Therapeutics.
How do I contact Intellia Therapeutics' investor relations team?: Intellia Therapeutics' physical mailing address is 40 Erie Street Suite 130, Cambridge MA, 02139. The company's listed phone number is (857) 285-6200 and its investor relations email address is [email protected]. The official website for Intellia Therapeutics is www.intelliatx.com. Learn More about contacing Intellia Therapeutics investor relations.

Intellia Therapeutics - NTLA Stock Price Target and Predictions

Analyst Price Target for NTLA

Current Consensus is Moderate Buy

Past Monthly Recommendations

Latest Recommendations

News Sentiment Rating

0.96 (Buy)

News Sentiment Over Time

Current Sentiment

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Intellia Therapeutics?

What is the current price target for Intellia Therapeutics?

What is the current consensus analyst rating for Intellia Therapeutics?

What other companies compete with Intellia Therapeutics?

How do I contact Intellia Therapeutics' investor relations team?